Approval · Notice of Compliance 23943 · 2020
VYVANSE: Notice of Compliance 23943
Issued July 23, 2020
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 23943
- Date
- July 23, 2020
- Company
- Takeda Canada IncorporatedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Administrative: Merger/Buy-out
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| VYVANSE | 02439603 | Marketed |
| VYVANSE | 02347156 | Marketed |
| VYVANSE | 02322951 | Marketed |
| VYVANSE | 02347164 | Marketed |
| VYVANSE | 02322978 | Marketed |
| VYVANSE | 02347172 | Marketed |
| VYVANSE | 02458071 | Marketed |
| VYVANSE | 02490226 | Marketed |
| VYVANSE | 02490234 | Marketed |
| VYVANSE | 02490242 | Marketed |
| VYVANSE | 02490250 | Marketed |
| VYVANSE | 02490269 | Marketed |
| VYVANSE | 02490277 | Marketed |
Medicinal ingredients
- LISDEXAMFETAMINE DIMESYLATE 10 MG per CAP
- LISDEXAMFETAMINE DIMESYLATE 20 MG per CAP
- LISDEXAMFETAMINE DIMESYLATE 30 MG per CAP
- LISDEXAMFETAMINE DIMESYLATE 40 MG per CAP
- LISDEXAMFETAMINE DIMESYLATE 50 MG per CAP
- LISDEXAMFETAMINE DIMESYLATE 60 MG per CAP
- LISDEXAMFETAMINE DIMESYLATE 70 MG per CAP